Clinical Trial

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

Study acronym: RESOLVE-2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-22; most recent amendment 2026-04-02.
Status change: Recruiting → Active, Not Recruiting 2025-12-22
Trial Details
NCT Number NCT07220629
Lead Sponsor NodThera Limited
Conditions Obesity
Enrollment 82 participants
Start Date 2025-10-02
Primary Completion 2026-08-21 (estimated)
Study Completion 2026-08-21 (estimated)
Updated on ClinicalTrials.gov 2026-04-08